张华捷,张庶民,庄辉
ZHANG Hua-jie~△,ZHANG Shu-min,ZHUANG Hui ( ~△Department of Microbiology

• 1:北京大学医学部病原生物学系
• 2:中国药品生物制品检定所血清室
• 3:北京大学医学部病原生物学系 北京100083
• 4:北京100050

摘要(Abstract)：

目的构建重组DT/bFGF融合蛋白表达载体,制备高纯度的DLF融合毒素。方法PCR扩增DT389和bFGF的编码DNA序列,经酶切和连接,克隆至表达载体pET-30a,转化E.coliBL21(DE3),鉴定阳性克隆菌落,经IPTG诱导表达融合蛋白DLF,镍离子螯合层析纯化,用Westernblot分析其抗原性。结果测序表明,插入片段可编码含545个氨基酸残基的融合蛋白DLF。SDS-PAGE分析表明,该融合蛋白可在大肠杆菌中表达,其表达量约占菌体总蛋白的20%,表达形式主要为包涵体。纯化后纯度达90%以上。Westernblot证实,该融合蛋白同时具有DT和bFGF两种抗原性。结论已成功构建DT/bF-GF表达载体,并获得较纯的DLF融合毒素。
Objective To construct the expression vector for DT/bFGF fusion protein and prepare highly purified DLF fusion toxin.Methods The DNA sequences encoding DT389 and bFGF were amplified by PCR and linked together by restriction endonuclease digestion and ligation,then cloned into expression vector pET-30a.The constructed plasmid pET-30a/DLF was transformed to E.coli BL21(DE3),and the positive clones were screened.The fusion protein was expressed by IPTG induction and purified by nickel ion affinity chromatography,then identified by Western blot.Results Sequence analysis showed that the inserted DNA fragment encoded fusion protein DLF consisting of 545 amino acid residues.SDS-PAGE showed that the fusion protein in a form of inclusion body was expressed in E.coli and contained about 20% of total somatic protein.The purity of the fusion protein reached more than 90% after purification and showed antigenicities of both DT and bFGF as proved by Western blot.Conclusion The expression vector of DT/bFGF fusion protein was successfully constructed,and highly purified DLF fusion toxin was obtained.

关键词(KeyWords)： 白喉毒素;碱性成纤维细胞生长因子;免疫毒素;融合蛋白
Diphtheria toxin(DT);Basic fibroblast growth factor(bFGF);Immunotoxin;Fusion protein

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张华捷,张庶民,庄辉
ZHANG Hua-jie~△,ZHANG Shu-min,ZHUANG Hui ( ~△Department of Microbiology

DOI: 10.13200/j.cjb.2006.04.6.zhanghj.001

参考文献(References)：

• [1]FitzGerald DJ,Kreitman RJ,Wilson W,et al.Recombinant immu-notoxins for treating cancer.Int J Med Microbiol,2004,293(7-8):577-582.
• [2]Choe S,Bennett MJ,Fujii G,et al.The crystal structure of diph-theria toxin.Nature,1992,357(6375):216-222.
• [3]Jeffers M,LaRochelle WJ,Lichenstein HS.Fibroblast growth fac-tors in cancer:therapeutic possibilities.Expert Opin Ther Targets,2002,6(4):469-482.
• [4]萨姆布鲁克J,拉塞尔DW.著.分子克隆实验指南.黄培堂,等.译.第3版.北京:科学出版社,2002.1723-1726.
• [5]Piascik P.FDAapproves fusion protein for treatment of lymphoma.J Am Pharm Assoc(Wash),1999,39(4):571-572.
• [6]Frankel AE,Powell BL,Hall PD,et al.PhaseⅠtrial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein(DT388GMCSF)for refractory or relapsed acute mye-loid leukemia.Clin Cancer Res,2002,8(5):1004-1013.
• [7]Weaver M,Laske DW.Transferrin receptor ligand-targeted toxin conjugate(Tf-CRM107)for therapy of malignant gliomas.J Neu-rooncol,2003,65(1):3-13.
• [8]Cohen KA,Liu TF,Cline JM,et al.Safety evaluation of DT388IL3,a diphtheria toxin/interleukin3fusion protein,in the cynomolgus monkey.Cancer Immunol Immunother,2005,54(8):799-806.